For the blood tube submission– Do you request that on every patient, even if they don't have a leukemic component? And what type of blood tube do you request we send the sample in?

We require at least 2 mL of whole blood in an EDTA-treated tube.

Other Questions

Back to Help Center

How can I help to advance precision medicine?

The more samples ImpriMed processes and the more clinical outcomes we receive from our customers, the more accurately our AI models are able to determine which drugs will work best for your patients. (Click to read more)

What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype. B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis. In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases. Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II. For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/

I have a leukemia patient. Can you run an assay on blood?

Yes, we do run assays on blood for a leukemia patient. Please send us at least 2 mL of whole blood in an EDTA tube.

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.

How does ImpriMed predict drug responses?

Our predictions are made by artificial intelligence (AI) models trained to predict clinical outcomes from patient data inputs. Clinical outcomes collected from oncologists include reports of progressive disease, stable disease, partial response, and complete response. Patient data used as inputs by the AI models include readings from our live-cell drug sensitivity assay, flow cytometry, PARR, and patient information.Models are re-trained periodically to incorporate new data and refine performance.